Catalyst Pharmaceutical CPRX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Catalyst Pharmaceutical (CPRX) Business Model and Operations Summary
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
Key Insights
Catalyst Pharmaceutical (CPRX) Core Market Data and Business Metrics
Latest Closing Price
$23.92Market Cap
$2.90 BillionPrice-Earnings Ratio
18.26Total Outstanding Shares
121.45 Million SharesTotal Employees
167Dividend
No dividendIPO Date
November 8, 2006SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
355 Alhambra Circle, Coral Gables, FL, 33134
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $-556,000 |
| Net Cash Flow, Continuing | $379.92 Million |
| Net Cash Flow | $379.92 Million |
| Net Cash Flow From Operating Activities | $239.81 Million |
| Net Cash Flow From Operating Activities, Continuing | $239.81 Million |
| Net Cash Flow From Investing Activities, Continuing | $-556,000 |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Diluted Average Shares | $124.94 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Cost Of Revenue | $68.84 Million |
| Net Income/Loss Attributable To Parent | $163.89 Million |
| Costs And Expenses | $275.47 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $163.94 Million |
| Comprehensive Income/Loss Attributable To Parent | $163.94 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $50,000 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Equity | $727.63 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Equity Attributable To Parent | $727.63 Million |
| Other Current Liabilities | $93.34 Million |
| Noncurrent Liabilities | $3.10 Million |
| Current Assets | $623.61 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||